 ADC Therapeutics NYSE:ADCT had its price objective lowered by Morgan Stanley from 53.00 to 52.00 in a report issued on Tuesday morning, Benzinga reports. The firm currently has an overweight rating on the stock. Separately, Zacks Investment Research cut ADC Therapeutics from a hold rating to a sell rating in a research report on Tuesday, ... 